
|Videos|August 4, 2020
Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)
Author(s)Alex Delaney-Gesing , David Hutton
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Advertisement
Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
2
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
3
Detecting peripheral retinal lesions in children with myopia
4
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
5























